Optional Endocrine Therapy of Investigator's Choice

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Locally Advanced or Metastatic Breast CancerMetastatic Breast Cancer

Phase 3

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Active, not recruitingNCT05296798

Hoffmann-La RocheLocally Advanced or Metastatic Breast Cancer

Start: 2022-07-18End: 2030-12-31Target: 922Updated: 2026-04-16

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

RecruitingNCT05894239

Hoffmann-La RocheMetastatic Breast Cancer

Start: 2023-09-08End: 2032-12-28Target: 230Updated: 2026-05-01

Related Papers

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

2025-06-121 citations

INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with <i>PIK3CA</i>-mutated, HER2-positive advanced breast cancer (HER2+ aBC).

Journal of Clinical Oncology2024-06-014 citations

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations

Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer

Cancer Research2024-05-021 citations

Abstract OT2-03-01: heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer

Cancer Research2023-03-013 citations